TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Race Oncology Ltd. ( (AU:RAC) ) just unveiled an update.
Race Oncology Limited announced the approval of its replacement Constitution by shareholders during its Annual General Meeting. This move signifies a strategic step in the company’s governance, potentially impacting its operational framework and stakeholder relations. The adoption of the new Constitution may align with Race Oncology’s broader goals of advancing its clinical programs and exploring strategic partnerships.
More about Race Oncology Ltd.
Race Oncology (ASX: RAC) is an ASX-listed Phase 3 clinical biopharmaceutical company focused on cancer care. Its primary product, RCDS1 (E,E-bisantrene), is an anticancer agent targeting G4-DNA & RNA binding, inhibiting the cancer growth regulator MYC. The company is advancing RCDS1’s proprietary formulation, RC220, for multiple oncology indications, including acute myeloid leukemia and non-small cell lung cancer. Race Oncology collaborates with various institutions and is exploring partnerships to enhance global access to RC220.
Average Trading Volume: 546,429
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$514.5M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.